Ann Oncol

1. PASSARO A, Wang J, Shah S, Bauml JM, et al
   Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl
   Ann Oncol. 2024;35:328-329.
   

   >> Share

   
   
2. MOIK F, Riedl JM, Ay C
   Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
   Ann Oncol. 2024;35:327.
   

   >> Share

   
   

   
   Anticancer Res

3. INOMATA M, Minatoyama S, Takata N, Hayashi K, et al
   Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy.
   Anticancer Res. 2024;44:1241-1245.
   

   >> Share

   
   
4. KINOSHITA H, Kinoshita S, Kamoda H, Hagiwara Y, et al
   Combined Auranofin and Celecoxib Suppresses the Local Progression and Pulmonary Metastases of Osteosarcoma In Vivo.
   Anticancer Res. 2024;44:1045-1049.
   

   >> Share

   
   

   
   Arch Pathol Lab Med

5. BLATNIK A, Dragos VS, Blatnik O, Stegel V, et al
   A Population-Based Study of Patients With Small Cell Carcinoma of the Ovary, Hypercalcemic Type, Encompassing a 30-Year Period.
   Arch Pathol Lab Med. 2024;148:299-309.
   

   >> Share

   
   

   
   BMC Cancer

6. CHEN K, Li S, Chen M, Jin Z, et al
   Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy.
   BMC Cancer. 2024;24:257.
   

   >> Share

   
   
7. WANG X, Zhao J, Mei T, Liu W, et al
   Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients.
   BMC Cancer. 2024;24:269.
   

   >> Share

   
   
8. XU M, Li C, Xiang L, Chen S, et al
   Assessing the causal relationship between 731 immunophenotypes and the risk of lung cancer: a bidirectional mendelian randomization study.
   BMC Cancer. 2024;24:270.
   

   >> Share

   
   

   
   Cancer

9. TAN AC, Lai GGY, Saw SPL, Chua KLM, et al
   Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
   Cancer. 2024 Feb 29. doi: 10.1002/cncr.35263.
   

   >> Share

   
   
10. MORGENSZTERN D
    The expanding role of circulating tumor DNA in resectable non-small cell lung cancer.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35268.
    

    >> Share

    
    
11. 
    Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study".
    Cancer. 2024 Feb 23. doi: 10.1002/cncr.35165.
    

    >> Share

    
    

    
    Cancer Cell

12. TONG X, Patel AS, Kim E, Li H, et al
    Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
    Cancer Cell. 2024 Feb 20:S1535-6108(24)00036-9. doi: 10.1016/j.ccell.2024.
    

    >> Share

    
    

    
    Cancer Lett

13. HAN R, Lin C, Lu C, Wang Y, et al
    Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.
    Cancer Lett. 2024;588:216762.
    

    >> Share

    
    
14. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
    Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Cancer Lett. 2024;584:216608.
    

    >> Share

    
    

    
    Cancer Sci

15. KAJIWARA N, Kakihana M, Maeda J, Kaneko M, et al
    Salivary metabolomic biomarkers for non-invasive lung cancer detection.
    Cancer Sci. 2024 Feb 28. doi: 10.1111/cas.16112.
    

    >> Share

    
    

    
    Clin Exp Metastasis

16. WIEGMANS AP, Ivanova E, Naei VY, Monkman J, et al
    Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer.
    Clin Exp Metastasis. 2024 Feb 28. doi: 10.1007/s10585-024-10270.
    

    >> Share

    
    

    
    Clin Lung Cancer

17. BORGHETTI P, Facheris G, Ciammella P, Galaverni M, et al
    Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort.
    Clin Lung Cancer. 2024;25:151-158.
    

    >> Share

    
    
18. GONZALEZ-MOSQUERA LF, Rous FA, Rogers A, Smith N, et al
    ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
    Clin Lung Cancer. 2024;25:e77-e80.
    

    >> Share

    
    
19. VERMA S, Young S, Kennedy TAC, Carvalhana I, et al
    Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors (SABR-DETECT).
    Clin Lung Cancer. 2024;25:e87-e91.
    

    >> Share

    
    
20. JENNINGS EM, Camidge DR, Gadgeel S, Barker S, et al
    Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC.
    Clin Lung Cancer. 2024;25:91-99.
    

    >> Share

    
    
21. INNO A, Picece V, Bogina G, Settanni G, et al
    Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report.
    Clin Lung Cancer. 2024;25:175-179.
    

    >> Share

    
    
22. ARDESHIR-LARIJANI F, Maniar R, Goyal S, Loehrer PJ, et al
    Trop-2 Expression and Its Impact on Survival in Thymic Epithelial Tumors: Brief Report.
    Clin Lung Cancer. 2024;25:180-185.
    

    >> Share

    
    
23. WALIANY S, Neal JW, Engel-Nitz N, Lam C, et al
    HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.
    Clin Lung Cancer. 2024 Jan 18:S1525-7304(24)00004.
    

    >> Share

    
    
24. WU Y, Zhao Y, Wu Y, Chen H, et al
    A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal Metastasis.
    Clin Lung Cancer. 2024 Feb 8:S1525-7304(24)00012.
    

    >> Share

    
    

    
    Eur J Cardiothorac Surg

25. WANG RR, Li MJ, Peng Q, Huang ZY, et al
    Validation of the ninth edition of the TNM staging system for Non-Small cell lung cancer with lobectomy in stage IA-IIIA.
    Eur J Cardiothorac Surg. 2024 Feb 29:ezae071. doi: 10.1093.
    

    >> Share

    
    
26. BARCELOS RR, Sugarbaker E, Kennedy KF, McAllister M, et al
    Time between imaging and surgery is not a risk factor for upstaging of clinical stage IA non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2024;65:ezae057.
    

    >> Share

    
    
27. GONZALEZ M, Ojanguren A, Figueroa S, Bedat B, et al
    Segmentectomy for lung cancer: Dig deeper.
    Eur J Cardiothorac Surg. 2024 Feb 24:ezae066. doi: 10.1093.
    

    >> Share

    
    
28. BERNARDI E, Diotti C, Bertolaccini L, Donghi S, et al
    Mediastinal cellulose pack mimicking lung cancer relapsing after lobectomy.
    Eur J Cardiothorac Surg. 2024 Feb 23:ezae065. doi: 10.1093.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

29. LUCIA F, Bourhis D, Pinot F, Hamya M, et al
    Prediction of Acute Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy Using Dose-Volume Parameters From Functional Mapping on Gallium 68 Perfusion Positron Emission Tomography/Computed Tomography.
    Int J Radiat Oncol Biol Phys. 2024;118:952-962.
    

    >> Share

    
    
30. FAROOQI AS, Yoder AK, Lin HY, Pasalic D, et al
    SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection.
    Int J Radiat Oncol Biol Phys. 2024;118:971-978.
    

    >> Share

    
    

    
    J Clin Oncol

31. HENICK BS, Herzberg BO, Concepcion-Crisol CP, Taylor AM, et al
    Controlled Chaos: Parsing Acquired Immunoresistance in Lung Cancer.
    J Clin Oncol. 2024 Feb 29:JCO2302339. doi: 10.1200/JCO.23.02339.
    

    >> Share

    
    
32. JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
    J Clin Oncol. 2024 Feb 28:JCO2302746. doi: 10.1200/JCO.23.02746.
    

    >> Share

    
    
33. JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
    J Clin Oncol. 2024 Feb 28:JCO2302744. doi: 10.1200/JCO.23.02744.
    

    >> Share

    
    
34. PIPER VALLILLO AJ, Viray H, Feldman J, Rangachari D, et al
    Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.
    J Clin Oncol. 2024 Feb 27:JCO2302417. doi: 10.1200/JCO.23.02417.
    

    >> Share

    
    

    
    Lung Cancer

35. LEE JD, Zheng R, Okusanya OT, Evans NR 3rd, et al
    Association between surgical quality and long-term survival in lung cancer.
    Lung Cancer. 2024;190:107511.
    

    >> Share

    
    
36. BAR J, Esteban E, Rodriguez-Abreu D, Aix SP, et al
    Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
    Lung Cancer. 2024;190:107506.
    

    >> Share

    
    

    
    Mol Carcinog

37. FURUSAWA T, Cavero R, Liu Y, Li H, et al
    Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer.
    Mol Carcinog. 2024 Feb 27. doi: 10.1002/mc.23705.
    

    >> Share

    
    

    
    Oncogene

38. TURKOWSKI K, Herzberg F, Gunther S, Weigert A, et al
    miR-147b mediated suppression of DUSP8 promotes lung cancer progression.
    Oncogene. 2024 Feb 23. doi: 10.1038/s41388-024-02969.
    

    >> Share

    
    
39. GAROFALO M, Quintavalle C, Di Leva G, Zanca C, et al
    Editorial Expression of Concern: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.
    Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02989.
    

    >> Share

    
    

    
    Oncologist

40. STRICKER T, Jain N, Ma E, Yu E, et al
    Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
    Oncologist. 2024 Feb 28:oyae022. doi: 10.1093.
    

    >> Share

    
    

    
    PLoS One

41. MORI S, Ueki Y, Hasegawa M, Nakamura K, et al
    Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study.
    PLoS One. 2024;19:e0298573.
    

    >> Share

    
    
42. WANG H, Tang H, Yuan S, Liang C, et al
    IL-17A deficiency inhibits lung cancer-induced osteoclastogenesis by promoting apoptosis of osteoclast precursor cells.
    PLoS One. 2024;19:e0299028.
    

    >> Share

    
    
43. YOO SJ, Park YS, Choi H, Kim DS, et al
    Prospective evaluation of deep learning image reconstruction for Lung-RADS and automatic nodule volumetry on ultralow-dose chest CT.
    PLoS One. 2024;19:e0297390.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share